{"brief_title": "Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)", "brief_summary": "This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug given daily will be superior to the lower dose of the same investigational drug given daily.", "condition": ["Heart Failure"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Losartan 50 mg", "Losartan 150 mg"], "description": ["50-mg losartan oral tablet", "100-mg losartan oral tablet + 50-mg losartan oral tablet"], "arm_group_label": ["Losartan 50 mg", "Losartan 150 mg"], "other_name": ["Losartan potassium", "Losartan potassium"], "criteria": "Inclusion Criteria: - Symptomatic heart failure with known or recently diagnosed intolerance of treatment with first-line medication for heart failure - May or may not be receiving an alternative and/or additional drug treatment", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Heart Failure", "Losartan"], "id": "NCT00090259"}